Imricor Medical Systems Inc.
IMR.ASXHealth Care
Development of MRI-compatible medical devices to carry out MRI-guided cardiac catheter ablation procedures.
Market Data
$1.755
+0.0%$615.1M
-100000.0x
$-0.115
0.00%
+0.0%
Latest Earnings
Appendix 4E and FY25 Financial Accounts
25 February 2026
Imricor Medical Systems reported a 70% revenue decline to $292k due to lower product sales, including customers participating in non-revenue clinical trials. Net loss improved to $25.3M from $29.7M due to smaller fair value charges on financial instruments, despite a 33% increase in adjusted net loss. The company raised $42.8M in March 2025 and received FDA clearance for key products in January 2026. Key points: FDA clearance received for NorthStar Mapping System and Vision-MR Diagnostic Catheter in January 2026; Successful equity raise of $42.8M in March 2025 improving liquidity position; Total liquidity of $40.8M at year end (cash plus marketable securities)
Recent Announcements
Becoming a substantial holder
controlled entities named in the list of 4 pages annexed to this notice and marked A (Daiichi Controlled Entities) became a substantial holder.
Appendix 4E and FY25 Financial Accounts
Imricor Medical Systems reported a 70% revenue decline to $292k due to lower product sales, including customers participating in non-revenue clinical trials. Net loss improved to $25.3M from $29.7M due to smaller fair value charges on financial instruments, despite a 33% increase in adjusted net loss. The company raised $42.8M in March 2025 and received FDA clearance for key products in January 2026. Key points: FDA clearance received for NorthStar Mapping System and Vision-MR Diagnostic Catheter in January 2026; Successful equity raise of $42.8M in March 2025 improving liquidity position; Total liquidity of $40.8M at year end (cash plus marketable securities)
Get real-time alerts for IMR
Receive AI-powered earnings summaries and instant notifications when Imricor Medical Systems Inc. releases results.
Register Free